List of Mitigare drug patents

Mitigare is owned by Hikma Intl Pharms.

Mitigare contains Colchicine.

Mitigare has a total of 5 drug patents out of which 0 drug patents have expired.

Mitigare was authorised for market use on 26 September, 2014.

Mitigare is available in capsule;oral dosage forms.

Mitigare can be used as method of using colchicine for the prophylaxis of gout flares.

The generics of Mitigare are possible to be released after 22 August, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675613 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(10 years from now)

US8927607 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(10 years from now)

US9399036 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(10 years from now)

US9555029 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(10 years from now)

US9789108 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(10 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 26 September, 2014

Treatment: Method of using colchicine for the prophylaxis of gout flares

Dosage: CAPSULE;ORAL

How can I launch a generic of MITIGARE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in